Doxorubicin Liposomal Suppliers & Bulk Manufacturers
Available Forms: Liposomal Injection (
Available Strengths: 20 mg/10 mL (2 mg/mL), 50 mg/25 mL (2 mg/mL)
Reference Brands: Doxil® , Caelyx® (EU & US)
Category:
Oncology Cancer Care
Doxorubicin Liposomal, sold as Doxil® (US) and Caelyx® (EU), is used for breast cancer, ovarian cancer, Kaposi’s sarcoma, and multiple myeloma. The liposomal formulation targets tumors more effectively, reducing systemic toxicity. Available in 20 mg/10 mL and 50 mg/25 mL concentrations, it is provided in single-use vials. Trusted by oncologists, it offers effective cancer treatment with minimized side effects in US and EU markets.
Doxorubicin Liposomal is available in Liposomal Injection (
and strengths such as 20 mg/10 mL (2 mg/mL), 50 mg/25 mL (2 mg/mL).
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Doxorubicin Liposomal is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Doxorubicin Liposomal can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Doxorubicin Liposomal, marketed as Doxil® (US) and Caelyx® (EU), is a chemotherapy agent used to treat breast cancer, ovarian cancer, Kaposi’s sarcoma, and multiple myeloma. Its liposomal formulation encapsulates the doxorubicin drug, allowing for more targeted delivery and reduced systemic toxicity compared to conventional doxorubicin. Available in 20 mg/10 mL and 50 mg/25 mL concentrations, it is supplied in single-use vials for oncology treatment. Sourced from GMP-compliant manufacturers, Doxorubicin Liposomal offers effective treatment for cancer patients while minimizing side effects, making it a trusted choice for healthcare providers in US and EU markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing